Back

Watch Compare

Medicus Pharma Ltd.

Data quality: 83%

Also listed as MDCXW Nasdaq

MDCX

Nasdaq Manufacturing Chemicals

$0.45

▼ $0.02 (-4.07%)

Mkt Cap: 17.61 M

Price

$0.45

Mkt Cap

17.61 M

Day Range

$0.44 — $0.47

52-Week Range

$0.37 — $8.94

Volume

734,224

Open $0.47

50D / 200D Avg

$0.89

49.61% below

50D / 200D Avg

$1.92

76.71% below

Quick Summary

Key Takeaways

Negative free cash flow of -22.78 M

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-4043.60%

Below sector avg (-51.02%)

ROIC-2003.07%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio0.92

Interest Coverage-174.08

Valuation

PE (TTM)

-0.37

Above sector avg (-1.98)

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)

Metric	Stock	Sector Median
P/E	-0.4	-2.0
P/B	—	5.1
ROE %	-4043.6	-51.0
Net Margin %	—	-150.2
Rev Growth 5Y %	—	9.3
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-47.28 M
ROE	-4043.60%	ROA	-431.55%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-22.78 M
ROIC	-2003.07%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	0.92
Interest Coverage	-174.08	Asset Turnover	N/A
Working Capital	-876,489	Tangible Book Value	-910,126
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0.37	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-129.36%
Market Cap	17.61 M	Enterprise Value	8.94 M
Per Share
EPS (Diluted TTM)	-2.74	Revenue / Share	N/A
FCF / Share	-0.58	OCF / Share	-0.58
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	48.17%
SBC-Adj. FCF	-24.29 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024
Revenue	—	—
Net Income	-47.28 M	-11.16 M
EPS (Diluted)	-2.74	-1.16
Gross Profit	—	—
Operating Income	-34.36 M	-11.18 M
EBITDA	—	—
R&D Expenses	7.72 M	3.53 M
SG&A Expenses	—	—
D&A	—	—
Interest Expense	-197,382.0	—
Income Tax	0.0	0.0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024
Total Assets	10.06 M	5.65 M
Total Liabilities	10.02 M	2.51 M
Shareholders' Equity	-67,554.0	3.13 M
Total Debt	—	—
Cash & Equivalents	8.71 M	4.16 M
Current Assets	9.89 M	5.38 M
Current Liabilities	9.94 M	2.31 M